Biologics are a pivotal part of modern medical treatments and are rapidly advancing as a therapeutic class due to their clinical success. With the growing importance of biologics in the pharmaceutical sector, there is significant interest in developing non-invasive delivery systems. Oral thin film delivery is particularly promising for biologics, allowing enhanced systemic absorption without invasive methods. At CD Formulation, our advanced oral thin film biologics delivery platform enables efficient development of oral thin films tailored to specific biologic compounds.
Fig.1 Development and characterization of chitosan films impregnated with insulin. (Concetta Giovino, et al., 2012)
Biologics are initially developed as injectables due to their limited stability through the gastrointestinal tract and solubility issues. The buccal route presents several advantages with the emergence of oral mucosal drug delivery routes. As an alternative site for biologics absorption, oral thin film biologics can bypass enzymatic degradation and the first-pass effect and improve bioavailability.
At CD Formulation, we provide comprehensive solutions for oral thin film biologics. With years of experience, we specialize in producing biologic-loaded thin films that address challenges such as low bioavailability and thermal sensitivity. Our oral thin film biologics delivery technologies include:
Oral thin film vaccine delivery technology shows great promise as a convenient, non-invasive, and potentially effective method for delivering vaccines that rapidly dissolve in the mouth, allowing for quick and easy administration without the need for needles or injections.
Oral thin film peptide delivery technology can improve bioavailability and rapid onset of action for peptides, as the oral mucosa can provide direct access to the bloodstream, bypassing the digestive system and potential degradation of the drug in the stomach and intestines. This delivery technology can enhance the therapeutic efficacy of peptide-based treatments.
CD Formulation has established an advanced oral thin film biologics development platform that can provide one-stop oral thin film biologics customization services, mainly including formulation development, biocompatibility study, drug loading and release, bioavailability study, stability and shelf-life study, etc.
Fig.2 Our workflow for Oral Thin Film Biologics Development. (CD Formulation)
Technology: Oral macromolecule delivery
Journal: European Journal of Pharmaceutical Sciences
IF: 4.3
Published: 2020
Results: The oral delivery of biopharmaceuticals requires the inclusion of absorption enhancers, protease inhibitors and a suitable carrier system. In this study, the design and characterization of chitosan/citrate films as carriers for oral macromolecule delivery. The results show that citric acid (3.5, 4 and 5 w/v %)-based chitosan solution could be used as a novel coating/sub-coating polymer for oral macromolecule delivery or as oral mucoadhesive films.
Fig.3 Design and characterization of chitosan/citrate films as carriers for oral macromolecule delivery. (Yousif H-E.Y. Ibrahim, et al., 2020)
CD Formulation has always been at the forefront of oral thin film formulation development. With the support of our advanced oral thin film platform, we provide customized formulation development services for oral thin film biologics. If you require our oral thin film biologics delivery technology services, please contact us by phone or email, and our colleagues will get back to you within three working days.
References